Download
s12028-021-01202-7.pdf 753,69KB
WeightNameValue
1000 Titel
  • Intracerebral Hemorrhage in COVID-19 Patients with Pulmonary Failure: A Propensity Score-Matched Registry Study
1000 Autor/in
  1. Lang, Corinna N. |
  2. Dettinger, Johanna S. |
  3. Berchtold-Herz, Michael |
  4. Utzolino, Stefan |
  5. Bemtgen, Xavier |
  6. Zotzmann, Viviane |
  7. Schmid, Bonaventura |
  8. Biever, Paul M. |
  9. Bode, Christoph |
  10. Müller-Peltzer, Katharina |
  11. Duerschmied, Daniel |
  12. Wengenmayer, Tobias |
  13. Niesen, Wolf-Dirk |
  14. Staudacher, Dawid L. |
1000 Erscheinungsjahr 2021
1000 Publikationstyp
  1. Artikel |
1000 Online veröffentlicht
  • 2021-02-23
1000 Erschienen in
1000 Quellenangabe
  • 34(3):739-747
1000 Copyrightjahr
  • 2021
1000 Lizenz
1000 Verlagsversion
  • https://doi.org/10.1007/s12028-021-01202-7 |
  • https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7899797/ |
1000 Publikationsstatus
1000 Sprache der Publikation
1000 Abstract/Summary
  • Background!#!Hypercoagulability in Coronavirus Disease 2019 (COVID-19) causes deep vein thrombosis and pulmonary embolism necessitating systemic anticoagulation. Case reports of intracerebral hemorrhages in ventilated COVID-19 patients warrant precaution. It is unclear, however, if COVID-19 patients with acute respiratory distress syndrome (ARDS) with or without veno-venous extracorporeal membrane oxygenation therapy (VV-ECMO) have more intracerebral hemorrhages (ICH) compared to other ARDS patients.!##!Methods!#!We conducted a retrospective observational single-center study enrolling all patients with ARDS from 01/2018 to 05/2020. PCR-positive SARS-CoV-2 patients with ARDS were allocated to the COVID-19 group. Propensity score matching was performed for age, VV-ECMO, and bleeding risk.!##!Results!#!A total of 163 patients with moderate or severe ARDS were identified, 47 (28.8%) in the COVID-19 group, and 116 (71.2%) in the non-COVID-19 group. In 63/163 cases (38.7%), VV-ECMO therapy was required. The ICU survival was 52.8%. COVID-19 patients were older, more often male, and exhibited a lower SOFA score, but the groups showed similar rates of VV-ECMO therapy. Treatments with antiplatelet agents (p = 0.043) and therapeutic anticoagulation (p = 0.028) were significantly more frequent in the COVID-19 patients. ICH was detected in 22 patients (13.5%) with no statistical difference between the groups (11.2 vs. 19.1% without and with SARS-CoV-2, respectively, p = 0.21). Propensity score matching confirmed similar rates of ICH in both groups (12.8 vs. 19.1% without and with SARS-CoV-2, respectively, p = 0.57), thus leveling out possible confounders.!##!Conclusions!#!Intracerebral hemorrhage was detected in every tenth patient with ARDS. Despite statistically higher rates of antiplatelet therapy and therapeutic anticoagulation in COVID-19 patients, we found a similar rate of ICH in patients with ARDS due to COVID-19 compared to other causes of ARDS.
1000 Sacherschließung
gnd 1206347392 COVID-19
lokal Aged, 80 and over [MeSH]
lokal Aged [MeSH]
lokal Respiratory Distress Syndrome/mortality [MeSH]
lokal Risk Factors [MeSH]
lokal COVID-19/complications [MeSH]
lokal COVID-19/therapy [MeSH]
lokal Cerebral Hemorrhage/epidemiology [MeSH]
lokal Critical Care [MeSH]
lokal COVID-19/mortality [MeSH]
lokal Respiratory Distress Syndrome/virology [MeSH]
lokal Male [MeSH]
lokal Cerebral Hemorrhage/virology [MeSH]
lokal Propensity Score [MeSH]
lokal Length of Stay [MeSH]
lokal Female [MeSH]
lokal ARDS
lokal Adult [MeSH]
lokal Humans [MeSH]
lokal Retrospective Studies [MeSH]
lokal Middle Aged [MeSH]
lokal COVID-19
lokal Extracorporeal Membrane Oxygenation [MeSH]
lokal Original Work
lokal Survival Rate [MeSH]
lokal Cerebral Hemorrhage/therapy [MeSH]
lokal Germany [MeSH]
lokal Young Adult [MeSH]
lokal Intracerebral hemorrhage
lokal Respiratory Distress Syndrome/therapy [MeSH]
lokal Respiration, Artificial [MeSH]
lokal Registries [MeSH]
1000 Liste der Beteiligten
  1. https://frl.publisso.de/adhoc/uri/TGFuZywgQ29yaW5uYSBOLg==|https://frl.publisso.de/adhoc/uri/RGV0dGluZ2VyLCBKb2hhbm5hIFMu|https://frl.publisso.de/adhoc/uri/QmVyY2h0b2xkLUhlcnosIE1pY2hhZWw=|https://frl.publisso.de/adhoc/uri/VXR6b2xpbm8sIFN0ZWZhbg==|https://frl.publisso.de/adhoc/uri/QmVtdGdlbiwgWGF2aWVy|https://frl.publisso.de/adhoc/uri/Wm90em1hbm4sIFZpdmlhbmU=|https://frl.publisso.de/adhoc/uri/U2NobWlkLCBCb25hdmVudHVyYQ==|https://frl.publisso.de/adhoc/uri/QmlldmVyLCBQYXVsIE0u|https://frl.publisso.de/adhoc/uri/Qm9kZSwgQ2hyaXN0b3Bo|https://frl.publisso.de/adhoc/uri/TcO8bGxlci1QZWx0emVyLCBLYXRoYXJpbmE=|https://frl.publisso.de/adhoc/uri/RHVlcnNjaG1pZWQsIERhbmllbA==|https://frl.publisso.de/adhoc/uri/V2VuZ2VubWF5ZXIsIFRvYmlhcw==|https://frl.publisso.de/adhoc/uri/Tmllc2VuLCBXb2xmLURpcms=|https://frl.publisso.de/adhoc/uri/U3RhdWRhY2hlciwgRGF3aWQgTC4=
1000 Hinweis
  • DeepGreen-ID: 8accea76984e412787de7351be199614 ; metadata provieded by: DeepGreen (https://www.oa-deepgreen.de/api/v1/), LIVIVO search scope life sciences (http://z3950.zbmed.de:6210/livivo), Crossref Unified Resource API (https://api.crossref.org/swagger-ui/index.html), to.science.api (https://frl.publisso.de/), ZDB JSON-API (beta) (https://zeitschriftendatenbank.de/api/), lobid - Dateninfrastruktur für Bibliotheken (https://lobid.org/resources/search)
1000 Label
1000 Dateien
1000 Objektart article
1000 Beschrieben durch
1000 @id frl:6445658.rdf
1000 Erstellt am 2023-04-28T10:57:19.792+0200
1000 Erstellt von 322
1000 beschreibt frl:6445658
1000 Zuletzt bearbeitet Fri Oct 20 16:04:57 CEST 2023
1000 Objekt bearb. Fri Oct 20 16:04:57 CEST 2023
1000 Vgl. frl:6445658
1000 Oai Id
  1. oai:frl.publisso.de:frl:6445658 |
1000 Sichtbarkeit Metadaten public
1000 Sichtbarkeit Daten public
1000 Gegenstand von

View source